title: Estrogenic and antiestrogenic down-regulation of estrogen receptor levels: evidence for two different mechanisms.
abstract: Preincubation of MCF-7 cells with estradiol (E2) produces a decrease of 3H-E2 binding capacity ("processing"); the strong antiestrogen methylhydroxytamoxifen (MHT) is also effective but with a approximately 100 fold lower efficiency. Parallel immunological measurement of estrogen receptor contents of the cells (ER-EIA from Abbott) revealed that the mechanisms by which these ligands operate are not of the same nature. Thus, while E2 produced a loss of the ER peptide, MHT increased it; indicating an accumulation of a non-binding form of the receptor under its treatment. Measurement of the binding capacity of the cells for 3H-ORG 2058 showed a decrease of PgR concentration after pre-incubation with MHT which contrasted with the classical E2-induced increase of the receptor. MHT at relatively low concentrations also antagonised the E2-induced decrease of 3H-E2 binding capacity; this property did not result from a difference in chemical structure between the ligands since bisphenol a weak estrogenic analogue of MHT failed to show a similar antagonistic activity. This property confers to MHT the ability to reduce the efficiency of E2 to induce PgR. Finally, actinomycin D a known antagonist of the E2-induced processing was found to be totally ineffective towards the MHT processing. This clearly confirmed that the term "processing" covers at least two distinct mechanisms.
authors.affiliation: Laboratoires d'Endocrinologie et de Cancérologie Mammaire, Institut J. Bordet, Brussels, Belgium.
authors.forename: M
authors.initials: M
authors.lastname: Gyling
authors.forename: G
authors.initials: G
authors.lastname: Leclercq
authors.forename: J C
authors.initials: JC
authors.lastname: Heuson
mesh_terms: D001943:Breast Neoplasms / Q000737:chemistry; D003609:Dactinomycin / Q000494:pharmacology; D015536:Down-Regulation; D004958:Estradiol / Q000494:pharmacology*; D004965:Estrogen Antagonists / Q000494:pharmacology*; D005260:Female; D006801:Humans; D011960:Receptors, Estrogen / Q000032:analysis* / Q000187:drug effects; D013629:Tamoxifen / Q000494:pharmacology; D014407:Tumor Cells, Cultured
chemical_list: D004965:Estrogen Antagonists; D011960:Receptors, Estrogen; D013629:Tamoxifen; D003609:Dactinomycin; D004958:Estradiol